EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immune-focused RBD nanoparticles induce cross-reactive, RBS-directed responses capable of variant-resistant SARS-CoV-2 neutralization

Kylie M Konrath, Kevin Liaw, Nicholas J Tursi, Madison E McCanna, Bryce M Warner, Ebony N Gary, Xizhou Zhu, Cory Livingston, Cara Monastra, Drew Frase, Neethu Chokkalingam, Alana Huynh und 21 weitere

PLOS Pathogens · 2026

DOI: 10.1371/journal.ppat.1013905 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, 2026. Verfasst von Kylie M Konrath und 32 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America. Hauptthemen laut MEDLINE: SARS-CoV-2, Antibodies, Viral, Antibodies, Neutralizing, Nanoparticles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NCI NIH HHS, Honorable Tina Brozman Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

New SARS-CoV-2 variants pose an ongoing threat due to persistent immune escape of natural and vaccine-induced immunity. The emergence of BA.1 (Omicron) produced a large antigenic shift in the spike protein, rendering many antibodies ineffective with concomitant loss of Emergency Use Authorization (EUA) status. While strains have evolved far from BA.1, re-emergence of variants from branches closer to BA.1 are of recent concern. Here, we engineered a self-assembling nanoparticle displaying RBD 4mut g5.1, an immunogen developed using structure-guided design to focus antibody responses to the receptor binding site (RBS) epitope and promote cross-reactivity by inclusion of four rationally selected BA.1 mutations in the RBS. Unlike multi-component RBD approaches, we demonstrate a single, rationally designed component is sufficient for generating broad immunity. We demonstrate that in both naïve and antigen-experienced mice, RBD 4mut g5.1 nanoparticle induced cross-reactive and durable antibody responses capable of potent neutralization of ancestral SARS-CoV-2 and many Omicron variants. RBD 4mut g5.1 provided heterologous protection at a memory timepoint. By showcasing how subtle changes in an epitope can trigger a diversified antibody response, this study offers a promising new avenue for developing vaccines that can more effectively tackle the ever-evolving threat of immune escape, not only against SARS-CoV-2 but potentially against a range of variable pathogens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Antibodies, ViralAntibodies, NeutralizingNanoparticlesSpike Glycoprotein, CoronavirusCOVID-19COVID-19 VaccinesAnimalsMiceCross ReactionsEpitopesHumansBinding SitesFemaleNanovaccinesProtein Subunit Vaccines

Substanzen

Antibodies, ViralAntibodies, NeutralizingSpike Glycoprotein, CoronavirusEpitopesCOVID-19 Vaccinesspike protein, SARS-CoV-2NanovaccinesProtein Subunit Vaccines

Autor:innen und Institutionen

  • Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America.
  • Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
  • Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.
  • Vaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, Canada.
  • Department of Biochemistry, Microbiology, and Immunology, University of Saskatchewan, Saskatoon, Canada.
  • National Center for Foreign Animal Disease (NCFAD), Canadian Food Inspection Agency, Winnipeg, Canada.

ORCID-Profile: Daniel W Kulp

Förderung

  • NIAID NIH HHS
  • NCI NIH HHS
  • Honorable Tina Brozman Foundation
  • NIH

Zitieren

APA

Konrath, K. M., Liaw, K., Tursi, N. J., McCanna, M. E., Warner, B. M., Gary, E. N., Zhu, X., Livingston, C., Monastra, C., Frase, D., Chokkalingam, N., Huynh, A., Shupin, N., Bayruns, K., Kriete, S., Kim, A., Park, J., Vendramelli, R., Truong, T., …, & Kulp, D. W. (2026). Immune-focused RBD nanoparticles induce cross-reactive, RBS-directed responses capable of variant-resistant SARS-CoV-2 neutralization. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1013905

Vancouver

Konrath KM, Liaw K, Tursi NJ, McCanna ME, Warner BM, Gary EN, et al. Immune-focused RBD nanoparticles induce cross-reactive, RBS-directed responses capable of variant-resistant SARS-CoV-2 neutralization. PLOS Pathogens. 2026. doi:10.1371/journal.ppat.1013905

BibTeX
@article{Konrath2026,
  author = {Konrath, Kylie M and Liaw, Kevin and Tursi, Nicholas J and McCanna, Madison E and Warner, Bryce M and Gary, Ebony N and Zhu, Xizhou and Livingston, Cory and Monastra, Cara and Frase, Drew and Chokkalingam, Neethu and Huynh, Alana and Shupin, Nicholas and Bayruns, Kelly and Kriete, Sinja and Kim, Amber and Park, Joyce and Vendramelli, Robert and Truong, Thang and Tierney, Kevin and Azaransky, Kimberly and Moffat, Estella and Embury-Hyatt, Carissa and Beer, Lynn A and Solanke, Oreoluwa and Walker, Susanne N and Kalia, Richa and Tang, Hsin-Yao and Humeau, Laurent M P F and Smith, Trevor R F and Kobasa, Darwyn and Weiner, David B and Kulp, Daniel W},
  title = {Immune-focused RBD nanoparticles induce cross-reactive, RBS-directed responses capable of variant-resistant SARS-CoV-2 neutralization},
  journal = {PLOS Pathogens},
  year = {2026},
  doi = {10.1371/journal.ppat.1013905}
}
Kostenlos starten →